Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of

circulating tumor-DNA (ct-DNA) epidermal growth factor receptor (EGFR) massive parallel sequencing (MPS) resistance-inducing mutation tyrosine-kinase Inhibitors

Journal

Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965

Informations de publication

Date de publication:
17 Mar 2020
Historique:
received: 08 01 2020
accepted: 17 02 2020
entrez: 28 3 2020
pubmed: 28 3 2020
medline: 28 3 2020
Statut: epublish

Résumé

In Non-Small-Cell Lung Cancer (NSCLC) patients treated with Tyrosine Kinase-Inhibitors (TKIs) therapy, the emergence of acquired resistance can be investigated by plasma monitoring of circulating tumor DNA (ctDNA). A series of 116 patients with

Identifiants

pubmed: 32215186
doi: 10.18632/oncotarget.27517
pii: 27517
pmc: PMC7082112
doi:

Types de publication

Journal Article

Langues

eng

Pagination

982-991

Déclaration de conflit d'intérêts

CONFLICTS OF INTEREST The authors have no conflicts of interest.

Références

Lung Cancer. 2013 Nov;82(2):294-8
pubmed: 24035188
Cancer. 2020 Jan 15;126(2):373-380
pubmed: 31769875
Clin Cancer Res. 2011 Mar 1;17(5):1169-80
pubmed: 21248300
J Thorac Oncol. 2015 Oct;10(10):1437-43
pubmed: 26295376
Clin Cancer Res. 2019 Nov 15;25(22):6644-6652
pubmed: 31439584
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
Clin Cancer Res. 2011 Mar 15;17(6):1616-22
pubmed: 21135146
Nat Med. 2014 May;20(5):548-54
pubmed: 24705333
N Engl J Med. 2005 Feb 24;352(8):786-92
pubmed: 15728811
J Clin Oncol. 2012 Jun 10;30(17):2063-9
pubmed: 22547605
PLoS Med. 2005 Mar;2(3):e73
pubmed: 15737014
JAMA Oncol. 2019 Feb 1;5(2):173-180
pubmed: 30325992
Clin Cancer Res. 2015 Jul 15;21(14):3196-203
pubmed: 25829397
ACS Med Chem Lett. 2015 Dec 18;7(1):2-5
pubmed: 26819655
J Med Chem. 2014 Oct 23;57(20):8249-67
pubmed: 25271963
J Thorac Oncol. 2014 Sep;9(9):1345-53
pubmed: 25122430
N Engl J Med. 2009 Sep 3;361(10):947-57
pubmed: 19692680
Clin Cancer Res. 2013 Apr 15;19(8):2240-7
pubmed: 23470965
N Engl J Med. 2010 Jun 24;362(25):2380-8
pubmed: 20573926
N Engl J Med. 2020 Jan 2;382(1):41-50
pubmed: 31751012
ACS Med Chem Lett. 2019 Aug 02;10(9):1322-1327
pubmed: 31531204
Lancet Oncol. 2020 Mar;21(3):373-386
pubmed: 32027846
Lancet Oncol. 2010 Feb;11(2):121-8
pubmed: 20022809

Auteurs

Fiamma Buttitta (F)

Laboratory of Diagnostic Molecular Oncology, Center for Advanced Studies and Technology (CAST), University of Chieti, Chieti, Italy.
Department of Medical and Oral Sciences and Biotechnologies, University of Chieti, Chieti, Italy.
Department of Pathology, SS Annunziata Clinical Hospital, Chieti, Italy.

Lara Felicioni (L)

Department of Pathology, SS Annunziata Clinical Hospital, Chieti, Italy.

Alessia Di Lorito (AD)

Department of Medical and Oral Sciences and Biotechnologies, University of Chieti, Chieti, Italy.

Alessio Cortellini (A)

Department of Oncology, San Salvatore Hospital, L'Aquila, Italy.

Luciana Irtelli (L)

Department of Oncology, SS Annunziata Clinical Hospital, Chieti, Italy.

Davide Brocco (D)

Department of Oncology, SS Annunziata Clinical Hospital, Chieti, Italy.

Pietro Di Marino (PD)

Department of Oncology, SS Annunziata Clinical Hospital, Chieti, Italy.

Donatella Traisci (D)

Department of Oncology, Floraspe Renzetti Hospital, Lanciano, Italy.

Nicola D'Ostilio (N)

Department of Oncology, Floraspe Renzetti Hospital, Lanciano, Italy.

Alessandra Di Paolo (AD)

Department of Oncology, Spirito Santo Hospital, Pescara, Italy.

Francesco Malorgio (F)

Department of Oncology, Spirito Santo Hospital, Pescara, Italy.

Pasquale Assalone (P)

Department of Oncology, "S.S. Giovanni Paolo II" Veneziale Hospital, Isernia, Italy.

Sonia Di Felice (SD)

Department of Oncology, Giuseppe Mazzini Hospital, Teramo, Italy.

Francesca Fabbri (F)

Department of Oncology, Giuseppe Mazzini Hospital, Teramo, Italy.

Giovanni Cianci (G)

Department of Oncology, Giuseppe Mazzini Hospital, Teramo, Italy.

Michele De Tursi (M)

Department of Medical and Oral Sciences and Biotechnologies, University of Chieti, Chieti, Italy.
Department of Oncology, SS Annunziata Clinical Hospital, Chieti, Italy.

Antonio Marchetti (A)

Laboratory of Diagnostic Molecular Oncology, Center for Advanced Studies and Technology (CAST), University of Chieti, Chieti, Italy.
Department of Medical and Oral Sciences and Biotechnologies, University of Chieti, Chieti, Italy.
Department of Pathology, SS Annunziata Clinical Hospital, Chieti, Italy.

Classifications MeSH